LDR | | 00000nmm u2200205 4500 |
001 | | 000000330665 |
005 | | 20241104131127 |
008 | | 181129s2017 ||| | | | eng d |
020 | |
▼a 9780438098114 |
035 | |
▼a (MiAaPQ)AAI10901870 |
035 | |
▼a (MiAaPQ)OhioLINK:osu1511979972361293 |
040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 248032 |
049 | 1 |
▼f DP |
082 | 0 |
▼a 616 |
100 | 1 |
▼a Russell, Luke. |
245 | 10 |
▼a Oncolytic Virus Expression of PTENalpha Directs Antitumor Immune Response. |
260 | |
▼a [S.l.] :
▼b The Ohio State University.,
▼c 2017 |
260 | 1 |
▼a Ann Arbor :
▼b ProQuest Dissertations & Theses,
▼c 2017 |
300 | |
▼a 109 p. |
500 | |
▼a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B. |
500 | |
▼a Adviser: Balveen Kaur. |
502 | 1 |
▼a Thesis (Ph.D.)--The Ohio State University, 2017. |
520 | |
▼a Brain tumors affect over 680,000 people in the USA, with malignant brain tumors accounting for approximately 20% of these patients. Malignant brain tumors are among the most aggressive and deadly tumors, and can be divided to primary tumors that |
520 | |
▼a Brain tumor treatment continues to be a major challenge in oncology. The standard of care for brain tumors consists of maximal surgical resection followed by radiotherapy and chemotherapy. However, despite continued research and new approaches f |
520 | |
▼a Oncolytic viral therapy is a promising novel therapy for brain tumors which recently gained FDA approval for the treatment of metastatic melanoma, and is in clinical trials for a variety of tumor indications, including brain tumors. Here we gene |
590 | |
▼a School code: 0168. |
650 | 4 |
▼a Neurosciences. |
690 | |
▼a 0317 |
710 | 20 |
▼a The Ohio State University.
▼b Neuroscience Graduate Studies Program. |
773 | 0 |
▼t Dissertation Abstracts International
▼g 79-12B(E). |
773 | |
▼t Dissertation Abstract International |
790 | |
▼a 0168 |
791 | |
▼a Ph.D. |
792 | |
▼a 2017 |
793 | |
▼a English |
856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T15000300
▼n KERIS |
980 | |
▼a 201812
▼f 2019 |
990 | |
▼a 관리자
▼b 관리자 |